reSee.it - Related Video Feed

We are making this dream a reality with this announcement. The COVID vaccine has proven to be highly effective, although its logistics were complex due to the new technology.

Vaccines are crucial for public health. There will be new vaccines developed, including for TB, malaria, and HIV. Misinformation about vaccines is a problem, especially in the US. We need to invest in vaccinations, as it has a significant return on investment. Life will not fully return to normal until the global population is vaccinated. We must prepare for future pandemics.

Vaccines are seen as magical but expectations should be tempered. Pfizer's vaccine is 95% effective, but efficacy drops over time. Boosters may be needed annually. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but we must adapt.

Research on potential pandemic pathogens, known as gain of function studies, has led to valuable public health insights. Previous NSABB reports support this. While I won't argue for the necessity of this research, there are many freely available studies showing how mutations identified through these studies have helped us prepare for epidemics and pandemics.

Pfizer is reportedly considering mutating the COVID virus to develop new vaccines, a topic discussed internally but not disclosed to the public. The process involves infecting monkeys with the virus to create mutations, which raises ethical concerns. While some argue this resembles gain-of-function research, Pfizer claims it is a different approach called directed evolution. The goal is to anticipate new variants and create vaccines in advance, potentially turning COVID into a profitable venture for the company. Concerns about the moral implications of such actions and the influence of government officials in the pharmaceutical industry were also raised, suggesting a troubling relationship between regulators and companies like Pfizer. The situation remains controversial, with ongoing discussions about transparency and public health risks.

We are having high-level and low-level meetings to address the challenges of the virus. We have learned from the past and are working on improvements in operations. This situation highlights the importance of research to keep up with the virus's mutations as it spreads.

mRNA vaccines have shown the potential of cell and gene therapy. Two years ago, most people would have refused gene or cell therapy, but the pandemic has increased acceptance of innovative treatments.

Our company is embracing cell and gene therapy, which has the potential to make a significant impact. The mRNA vaccines are a prime example of this. Just a couple of years ago, if we had asked the public if they would be willing to undergo gene or cell therapy, the majority would have refused. However, the pandemic has changed people's perspectives and made them more open to innovative solutions.

Now that we're coming out of the pandemic, the issue of variants will mainly be discussed by specialists. They will talk about the impact of these variants in conferences. Currently, the planned vaccination covers all variants. And does vaccination limit the emergence of new variants? Absolutely, by reducing the number of affected individuals. It decreases the portion of the population where the virus can multiply and mutate, thus leading to new variants. So, vaccination is absolutely essential to control the situation.

I will monitor the effects of the COVID vaccine on the economy. Excess deaths are decreasing, but still remain at 5-10% in many countries. Long-term impacts like cancer are emerging, which will harm the economy for years.

There will be another pandemic; it's just a matter of time. The annual risk is around 2% to 3%, and we must prepare for future outbreaks, including unexpected ones, often referred to as "black swans." The work we do now is crucial for readiness, as we will inevitably face new challenges and different types of viruses. It's essential to acknowledge that surprises will arise, and we need to be equipped to handle them.

We are launching partnerships to intensify the search for a vaccine, strengthen treatments, and increase diagnostic capacities for COVID-19. Our goal is to ensure equitable access to improved diagnostics, accelerated therapies, and the development of a safe and effective vaccine.

The NIH is developing a universal vaccine that addresses the entire phylum of viruses. This vaccine mimics natural immunity and is effective against any kind of mutation. It doesn't drive the virus to mutate. The researchers believe it could be effective not only against coronaviruses but also against influenza. The vaccine is described as much safer and much more effective. The exchange then notes that Mark, did you take your question again? and Mark is prompted to ask his question.

The speaker explains that all profits generated during the COVID period were reinvested, with the main focus of investment placed in the cancer field. This choice was driven by several factors: first, the organization already had strong capabilities in cancer; second, there was a significant opportunity presented by the acquisition of C Gen that would allow them to intensify their efforts in this area. The speaker emphasizes that cancer holds a deeply personal significance, impacting the world broadly and affecting colleagues personally as well. Given these motivations, cancer was identified as a meaningful and strategic pivot for the organization’s reinvestment strategy. The speaker frames the shift in emphasis as a continuation of prioritizing global health impact, contrasting it with the earlier impact of addressing COVID. The closing line underscores the aspirational goal: after helping to mitigate COVID, the organization aims to contribute to reducing the burden of cancer, positioning the pivot as a deliberate and purposeful progression in their mission to “save the world” from major health threats.

Pfizer is considering mutating the COVID virus to create new vaccines, but they don't want the public to know. They are conducting experiments on live monkeys to study the virus and its mutations. Pfizer believes that by controlling the mutations in their labs, they can develop vaccines for new variants before they even emerge in nature. This would be a lucrative business model for them. The pharmaceutical industry has a revolving door with government officials, which benefits the industry but is bad for everyone else. The comments made by Pfizer's Jordan Walker show a lack of moral compass and a disregard for public health. Pfizer believes it has successfully captured the regulatory apparatus and can bypass laws. This is an ongoing story that needs attention.

We are working on developing new vaccines like TB and HIV using mRNA technology to make them high quality and low cost. Current COVID vaccines are not perfect, so we are working on new versions with longer-lasting protection for diseases like measles and tuberculosis. The mRNA technology also shows promise for cancer vaccines and rapid adaptation to future pandemics. We are even exploring using this technology for animal vaccines.

Big pharma will likely profit significantly from this medication, which is intended for long-term or potentially lifelong use.

Vaccines are seen as magical, but expectations may need to be lowered. Pfizer's vaccine is 95% effective, but efficacy rates can fluctuate. Protection may only last a year, requiring annual shots. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but there is hope for improvement in the next 5 years.

Pfizer is considering mutating the COVID virus to create new vaccines, but they don't want the public to know. They are conducting experiments on live monkeys to study the virus and its mutations. Pfizer believes that by controlling the mutations in their labs, they can develop vaccines for new variants before they even emerge in nature. This would be a lucrative business model for them. The pharmaceutical industry has a revolving door with government officials, which benefits the industry but is bad for everyone else. The comments made by Pfizer's Jordan Walker show a lack of moral compass and a disregard for public health. Pfizer believes it has successfully captured the regulatory apparatus and can circumvent laws. Governments are turning a blind eye to this unethical behavior.

We ensure there is enough capacity and competition for vaccines, leading to lower prices and the development of new vaccines. This includes vaccines for TB, malaria, HIV, and even COVID-19. To improve vaccines, we aim for longer duration and broader coverage, and plan to replace needles with patches. The pandemic has shown that we have not invested enough in these innovations. Our partners in India play a crucial role in achieving these breakthrough products.

Vaccines generate significant profits for companies. Adding just one vaccine to the infant child schedule can result in $1 billion in annual sales. The widespread COVID-19 vaccination has been highly lucrative for Pfizer, earning them $54 billion in 1.5 years. Moderna, on the other hand, made $56 billion, while Moderna made $34 billion during the same period.

We are working on developing new vaccines for diseases like TB, HIV using mRNA technology. The goal is to create high-quality, low-cost vaccines that can be used for various illnesses. Current COVID vaccines have limitations, so we are working on next-generation vaccines with longer-lasting protection. mRNA technology also shows promise for cancer vaccines and potential future pandemics. Additionally, we are exploring using this technology for animal vaccines.

In the video, the speaker mentions that in the future, there will be more variants of a certain subject. This is biologically plausible, and the speaker suggests that the more we vaccinate, the higher the chances of new variants emerging.

We are discussing vaccine development in response to new variants and subvariants. Currently, we have the advantage of increased manufacturing capacity compared to 2020. Back then, we only produced 100,000 doses in a year, but now we are capable of producing much more to address the ongoing challenges posed by different strains of the virus.

Our company is embracing cell and gene therapy, which has the potential to make a significant impact. mRNA vaccines are an example of this type of therapy. Two years ago, if we had asked the public if they would be willing to undergo gene or cell therapy, the refusal rate would have been around 95%. However, the pandemic has made people more open to innovation in ways that were previously unimaginable.